THUNDERCOMM
15.3.2023 04:57:35 CET | Business Wire | Press release
Thundercomm, a world leading IoT product and solution provider, announces the release of new offerings in its smart IoT module portfolio to lower the barriers to enter the market and accelerate innovation in various AIoT industry segments, including robotics, handheld devices, tablets and smart cameras.
TurboX C2210 SOM is powered by the Qualcomm® QRB2210 System-on-Chip (SoC). It's designed with an optimized Linux operating system, discrete memory for more memory options to save the cost, and system fast boot, supports 1080P@30FPS video decode and a long life cycle to 2028, aiming to bring advanced features to entry-level devices with better performance and improved power consumption. The TurboX C2210 SOM supports the Linux system and can be applied to a variety of products like entry-tier robotics, e-scooter, smart home dock, smart camera and rugged handheld, etc.
TurboX C4210 SOM is powered by the Qualcomm® QRB4210 SoC. It features triple ISPs for advanced dual-camera experience, dedicated Compute DSP for computer vision and video post-processing. It's designed to support advanced graphics, bringing high value features to mid-tier devices. It's an ideal platform for both industrial and consumer applications requiring high data rates multimedia function, and can be applied to a broad range of devices including robotics, dash camera, video conference, smart retail, etc.
TurboX C5430 SOM integrates the Qualcomm® QCS5430 SoC, a 6nm processor with superior performance, power efficiency, premium connectivity, and 3.5 TOPS computing power. It supports 4K@30FPS video decode and 4K@30FPS video encode, Wi-Fi 6E, long range bluetooth, four MIPI CSIs, as well as a rich set of peripheral interfaces. The C5430 SOM is a high performance AIoT SOM for building handheld devices, industrial robots, service robots, Edge Box, providing customers with hardware interfaces and software SDK to validate functions and build the prototype quickly.
“Robotics industry is growing faster than ever as technology continuously advances in 5G, computing power and AI. Today, we see robots in almost every aspect of our lives, helping us do much more than we can do alone. Our newly released C2210 SOM and C4210 SOM will unlock the potential of more innovations in robotics, lowering the barriers for brands to enter and compete efficiently in this growing market,” said Pier Zhang, Director of Product Marketing at Thundercomm. “We are offering not only the hardware SOM and dev kits, but also the robot brain, software solutions to help customers build future-proof robot products faster and cost-effectively.”
“We congratulate Thundercomm on the launch of their industry leading SOMs. Recognizing the innovation of these new products, Qualcomm Technologies recently announced Qualcomm® Robotics RB1 and RB2 Development Kits are based on TurboX C2210 and C4210 respectively,” said Dev Singh, vice president, business development, and head of building, enterprise and industrial automation, Qualcomm Technologies, Inc. “Boosting a suite of complete robotics capabilities, including pre-integrated sensors from TDK, cameras, and AI SDKs, our development kits will enable developers to more easily prototype everyday robotics applications thus helping push the IoT ecosystem forward.”
The Qualcomm Robotics RB1 and RB2 Development Kit and SOMs of TurboX C2210, C4210, C5430 are available now for evaluation and testing.
About Thundercomm
Thundercomm, a joint venture between Thunder Software Technology Co., Ltd and Qualcomm (China) Holding Co. Ltd., a subsidiary of Qualcomm Technologies, Inc., was established to accelerate innovation in the Internet of Things and automotive industry, providing one-stop solutions powered by Qualcomm Technologies. Through its capabilities in operating systems including Android, Linux, and others, abroad software and on-device AI technology portfolio, and a global sales and support network, Thundercomm is a valuable and trusted partner to global customers aiming to build high-quality, next-generation products and shorten time-to-commercialization. Learn more at www.thundercomm.com
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314006083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cegid Closes Acquisition of Shine to Create Europe's First Complete AI-Driven Platform for SMBs and Accountants8.6.2026 09:28:00 CEST | Press release
Accelerates Cegid’s trajectory to become the leading European financial solutions hub integrating e-invoicing, accounting, digital finance, payment services and accounts, and HR solutionsTransaction supported by new €1.1 billion debt financing facility secured from leading direct credit funds, underscoring Cegid’s strong business performance and unique leadership positioning in rapidly evolving software sector Cegid, a European leader in cloud management solutions for professionals in the finance (treasury, tax, ERP), human resources (payroll, talent management), accountancy, retail and entrepreneurship sectors, today announced the completion of its acquisition of Shine. The transaction creates the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe. Shine – a fast-growing European fintech unicorn providing electronic invoicing, accounting, business accounts, and payroll software to small and medium-sized businesses across Eu
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom